Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, used to control obesity and type 2 diabetes, are associated with changes in food purchasing in favour of healthier options. This result, published in the journal JAMA Network Open, was obtained by analysing nearly two million shopping receipts from more than 1,100 participants in Denmark. Those who started treatment with GLP-1 drugs began to make purchases with fewer calories, sugars, saturated fats and carbohydrates, along with a modest increase in protein content. A decrease in the purchase of ultra-processed foods was also observed.

An analysis published in the medical journal The BMJ points out that lifestyle changes recommended by doctors to people with obesity, focusing on calorie restriction and increased physical activity, have little effect on long-term weight loss, fail to significantly reduce cardiovascular risks and, yet, can lead to discrimination, stigmatisation and eating disorders. The authors also point out that weight alone is an inadequate measure of a person's health, as reflected in recent clinical guidelines, and propose a ‘health for all sizes’ approach with effective, patient-centred care.

According to the World Health Organisation (WHO), the prevalence of obesity worldwide has increased by more than 100 % between 1990 and 2022. This reality has been and is constantly reflected in the media, but not always narrated or illustrated in the right way. Here are some tips on how to report on this disease from experts, international guidelines and specialised image banks.